Dominic Pollard of Cancer Research Horizons and Dr. Pamela Bush of Predictive Oncology discuss the potential impact of their collaboration and how it can advance cancer drug development. This alliance between the world’s largest private funder of cancer research, with 11 marketed drugs and 150 active licenses, and the incorporation of our AI-driven, machine-learning PEDAL platform with access to an extensive biobank of tumor-specific samples, represents a promising win for patients, not just in the UK or US, but worldwide.

White Paper
Repurposing Drugs for Cancers of the Breast, Colon, and Ovary using Active Machine Learning and Biobank of DTC’s
Drug repurposing using the Predictive Oncology machine learning approach and proprietary biobank of frozen dissociated tumor cells (DTCs) is outlined in this new white paper.